Nanobiotix announced that the U.S. Food and Drug Administration accepted a protocol amendment to its pivotal Phase 3 study, NANORAY‑312, for locally advanced head and neck squamous cell carcinoma. The amendment, submitted by the study’s global sponsor Johnson & Johnson, was approved on May 4, 2026.
The amendment removes the previously planned interim analysis and shortens the final analysis by requiring fewer events, allowing the study’s readout to occur sooner. Nanobiotix expects the modified final analysis to be completed in the same timeframe as the interim analysis that was originally scheduled, thereby accelerating the overall development timeline.
By expediting the study’s readout, the company can pursue a faster global registration pathway for its lead product, NBTXR3 (also known as JNJ‑1900). The accelerated schedule also positions Nanobiotix to receive milestone payments from Johnson & Johnson earlier, potentially amounting to hundreds of millions of dollars, and could open the door to earlier revenue generation once the product is approved.
NBTXR3 is a first‑in‑class therapy composed of functionalized hafnium oxide nanoparticles that are injected once into the tumor and then activated by radiotherapy. The Phase 3 trial enrolls patients with locally advanced head and neck squamous cell carcinoma who are ineligible for platinum‑based chemotherapy, a population that represents a significant unmet medical need.
The partnership with Johnson & Johnson, which holds the global license for NBTXR3, has already yielded a $20 million milestone payment in May 2024 and provides a clear pathway for future payments tied to regulatory milestones. With a cash runway that extends into mid‑2026, the company is well positioned to capitalize on the accelerated development schedule and the broader potential of NBTXR3 across other solid tumors treated with radiotherapy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.